FDA Class I Recall: Nova StatStrip Gen 2.0 May Assign Results to the Wrong Patient
FDA has classified the recall of Nova Biomedical's StatStrip Glucose Hospital Meter Systems (Gen 2.0) as Class I because retained barcode information may assign glucose results to the wrong patient or quality-control identifier.
Decision support
Decision summary
Official recall information is separated from MedTech Current editorial analysis.
Official recall information
What happened
Nova Biomedical is removing affected StatStrip Glucose Hospital Meter Systems (Gen 2.0) pending a software update, with interim mitigations for users lacking an alternative device. FDA has classified the recall as Class I. Previous patient or quality-control (QC) information may remain on screen after a new barcode scan. Accepting that information can misdirect a result without affecting the analytical accuracy of the glucose measurement.
MedTech Current analysis
Why it matters
Patient-result linkage can create a serious safety risk even when analytical glucose accuracy is unaffected. This recall concerns specified Gen 2.0 systems, not earlier StatStrip generations, and highlights the safety significance of the data path between testing and the patient record.
Official recall information
Official actions
According to FDA's current communication and Nova Biomedical's revised October 5 customer notice:
- Where integrated admission, discharge and transfer (ADT) data are available, enable “Validate Patient ID's” in NovaNet. This feature requires ADT integration.
- Set operator logoff to “Test” so the meter logs the operator out after each test.
- Immediately flag or remove misassigned EMR results under facility procedures and promptly notify the treating team.
- Stop using affected meters if an alternative device is available. Without an alternative, continue the specified mitigations until the software fix is available.
- After each barcode scan, match the displayed patient ID, name, date of birth and other identifiers to the patient before accepting.
- Check the patient ID again when the result appears; the earlier scan check does not establish that the result-screen ID is correct.
- Immediately notify the administrator of any result assigned to the wrong patient.
- Circulate the revised notice to all facility end users and place copies where meters are stored and used.
- Complete and return the revised acknowledgment form, even if the original form was already submitted.
Detailed recall information
Detailed sourced information from the published Recall Brief follows.
What changed
Nova Biomedical is removing affected StatStrip Glucose Hospital Meter Systems (Gen 2.0) pending a software update, with interim mitigations for users lacking an alternative device. FDA has classified the recall as Class I. Previous patient or quality-control (QC) information may remain on screen after a new barcode scan. Accepting that information can misdirect a result without affecting the analytical accuracy of the glucose measurement.
The FDA describes potential consequences including inappropriate insulin administration, delayed treatment and failure to treat the intended patient. Its current notice states that Nova reported one serious injury and no deaths as of October 5, 2026.
The October 20 FDA posting concerns an existing recall. FDA’s current notice describes a July 31 customer letter revised on October 5; the database separately records July 29 as initiation. Nova plans a phased software-update rollout in November 2026. That is a target, not confirmation that a fix is available.
Who and what are affected
The FDA communication covers Gen 2.0 only, across all firmware versions. Nova’s revised notice includes all serial numbers of the two products below. Earlier generations, including Gen 1.86, are excluded.
| Product | Model | UDI-DI in current FDA notice |
|---|---|---|
| StatStrip Glucose Hospital Meter System | 63685 | 00385480636858 |
| Glucose Hospital Meter System Multipack | 66739 | 00385480636858 |
The corresponding U.S. recall numbers are Z-3128-2026 and Z-3129-2026. Other glucose/ketone products in Nova’s global announcement are outside this brief’s FDA-notice scope.
What affected organizations should do
Affected healthcare facilities
According to the current FDA communication:
- Where integrated admission, discharge and transfer (ADT) data are available, enable “Validate Patient ID’s” in NovaNet. This feature requires ADT integration.
- Set operator logoff to “Test” so the meter logs the operator out after each test.
- Immediately flag or remove misassigned EMR results under facility procedures and promptly notify the treating team.
Clinical users
The FDA communication gives these interim instructions:
- Stop using affected meters if an alternative device is available. Without an alternative, continue the specified mitigations until the software fix is available.
- After each barcode scan, match the displayed patient ID, name, date of birth and other identifiers to the patient before accepting.
- Check the patient ID again when the result appears; the earlier scan check does not establish that the result-screen ID is correct.
- Immediately notify the administrator of any result assigned to the wrong patient.
Customers receiving the revised notice
Nova’s October 5 advisory asks affected customers to:
- Circulate the revised notice to all facility end users and place copies where meters are stored and used.
- Complete and return the revised acknowledgment form, even if the original form was already submitted.